Zacks Investment Research upgraded shares of vTv Therapeutics Inc (NASDAQ:VTVT) from a hold rating to a buy rating in a research note released on Tuesday, May 9th. Zacks Investment Research currently has $6.00 target price on the biotechnology company’s stock.
According to Zacks, “vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company’s drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina. “
Other analysts have also issued research reports about the stock. HC Wainwright set a $13.00 price target on shares of vTv Therapeutics and gave the company a buy rating in a report on Thursday, May 4th. Canaccord Genuity reissued a buy rating on shares of vTv Therapeutics in a report on Tuesday, February 28th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $24.00 target price on shares of vTv Therapeutics in a report on Thursday, March 30th. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of Buy and an average price target of $14.40.
vTv Therapeutics (NASDAQ:VTVT) traded down 2.17% on Tuesday, reaching $4.96. The company had a trading volume of 23,989 shares. vTv Therapeutics has a 12 month low of $4.65 and a 12 month high of $7.50. The stock has a 50 day moving average of $5.58 and a 200 day moving average of $5.53. The firm’s market capitalization is $48.08 million.
vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.20 million. On average, analysts anticipate that vTv Therapeutics will post ($1.15) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://sportsperspectives.com/2017/05/19/vtv-therapeutics-inc-vtvt-lifted-to-buy-at-zacks-investment-research-updated.html.
In other vTv Therapeutics news, Director Paul G. Savas purchased 10,000 shares of the stock in a transaction on Friday, March 31st. The shares were purchased at an average cost of $6.50 per share, for a total transaction of $65,000.00. Following the purchase, the director now owns 66,435 shares of the company’s stock, valued at $431,827.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. purchased a new position in vTv Therapeutics during the third quarter valued at $1,438,000. Renaissance Technologies LLC raised its position in vTv Therapeutics by 24.3% in the fourth quarter. Renaissance Technologies LLC now owns 60,900 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 11,901 shares in the last quarter. Alyeska Investment Group L.P. raised its position in vTv Therapeutics by 31.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 213,200 shares of the biotechnology company’s stock valued at $1,030,000 after buying an additional 51,301 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in vTv Therapeutics during the first quarter valued at $917,000. Finally, Essex Investment Management Co. LLC purchased a new position in vTv Therapeutics during the first quarter valued at $261,000. Institutional investors own 12.18% of the company’s stock.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for vTv Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.